Afghanistan

Albania

Andorra

Armenia

<h4 class="MsoListParagraph" style="text-indent: -0.25in; text-align: left; line-height: 1.3;">The global pharmaceutical company has signed a contract with MODON for a plot of land to establish its research and manufacturing complex in the Kingdom.</h4>
<h4 class="MsoListParagraph" style="text-indent: -0.25in; text-align: left; line-height: 1.3;">The agreement marks the first step in EVA Pharma’s long-term investment strategy in Saudi Arabia.</h4>
<h4 class="MsoListParagraph" style="text-indent: -0.25in; text-align: left; line-height: 1.3;">The Saudi pharmaceutical complex will produce 990 million healthcare solutions annually.&nbsp;</h4>
Riyadh, Saudi Arabia; 26 September 2023--&nbsp;EVA Pharma, one of the fastest-growing pharmaceutical companies in the Middle East and Africa (MEA) region, signed a contract today with the Saudi Authority for Industrial Cities and Technology Zones, known as MODON, to attain a 50,517 sqm plot of land in Sudair City, for its state-of-the-art research and manufacturing complex in the kingdom.
The plot attained, facilitated by MODON, will house a full-fledged industrial complex that will cater to a diverse spectrum of therapeutic domains with plans to launch over 150 pharmaceutical products spanning biologics, vaccines, immunosuppressants, oncology, and high-potency medications, which require specialized containment technology. With a research &amp; development center at the heart of its industrial complex, EVA Pharma will bring the latest medical advancements closer while helping it respond more accurately to changing patient needs through research and collaboration with local universities and hospitals.
Commenting on the agreement, Engineer Majid bin Rafid Al-Arqobi, CEO of Saudi Authority for Industrial Cities and Technology Zones “Modon”, explained; The strategic partnership initiated by Modon with EVA Pharma comes within the framework of its role to localize the medical and pharmaceutical industries in the Kingdom, create an ideal environment attractive to foreign investments, and strengthen the national export system as an important factor for achieving a prosperous economy in line with the objectives of the National Industrial Strategy and the aspirations of the Saudi Vision 2030.
He added that, "Modon" provides innovative products and services that support the national industrial system. The land allocated for investment in 36 industrial cities has risen to about 135.6 million square meters, the developed areas of more than 202 million square meters, and industrial cities have 6,055 factories, including 1,263 ready factories.
Expressing his enthusiasm about the venture, Riad Armanious, CEO of EVA Pharma, said: “EVA Pharma is not just scaling its physical presence in the Kingdom; we are planting deep roots here. Our commitment to the Saudi people’s health is steadfast, and our investment in local manufacturing is a testament to that commitment. EVA Pharma's investment in local manufacturing not only bolsters the company's presence but also signifies a broader commitment to enhancing the region’s pharmaceutical capabilities, fostering innovation, catalyzing tech transfer, and creating employment opportunities, all while contributing to the growth and prosperity of Saudi Arabia.”
“We recognize the opportunities that Saudi Arabia has to offer. Thanks to the unwavering support of the Saudi Food and Drug Authority (SFDA) we can expand on our mission and contribute to the well-being of the Saudi community as a local emerging manufacturer in the Kingdom. Additionally, we recognize the need to work collaboratively with healthcare professionals and institutions to develop tailored solutions to the most demanding health challenges in the kingdom. We aim to be more than just a pharmaceutical company; we aspire to be a trusted partner in healthcare and to contribute to Saudi’s national health goals in line with Vision 2030.” added Armanious.
EVA Pharma announced the final conceptual design of its upcoming industrial complex today, a process that was initiated in June 2023. With the groundbreaking ceremony scheduled for late 2023, the first manufacturing phase is set to begin in April 2025, reaching full operational capacity in 2026 to produce 990 million units annually, offering 807 employment opportunities and contributing to the local economy.
This industrial complex, situated in Sudair near Riyadh, aims to become a center of gravity for pharmaceutical manufacturing in the region. It will comprise an R&amp;D center and five pharmaceutical factories, including one for biologics and oncology products, another for oral dosage forms like DPIs, Bi-layer, and ODT, an immunosuppressants facility, and a vaccines production unit.
Designed by IO, a German consultancy specializing in the implementation of complex industrial projects, EVA Pharma's Saudi complex embodies a green circular economy approach. It minimizes waste and optimizes resource usage through advanced technologies like AI and IoT to ensure energy efficiency in the hot Saudi Arabian climate. The complex's commitment to water stewardship practices safeguards this vital resource and places a strong emphasis on green chemistry principles. Additionally, it promotes transparent supply chains, adheres to CGMP regulations, and sets a new industry standard through the adoption of sustainable packaging procedures.
Today’s agreement marks a new milestone for EVA Pharma, which has established its strong foothold in the region since 1997, through a focused approach to research and innovation in the pharmaceuticals space. With a presence in more than 40 countries, EVA Pharma produces every day over a million packs of 300+ healthcare solutions at its three internationally accredited facilities.
&nbsp;
About EVA Pharma
<span style="mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi;">EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
<span style="mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi;">The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
<span style="mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi;">EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa while operating in more than 40 countries worldwide.

thumbnail_news_website_size_copy_1_f612be87bd.webp

news_website_size_copy_1_f612be87bd.webp

Press Release

In partnership with MODON EVA Pharma to Obtain Over 50,000 sqm of Land for an Industrial Complex Investment in Saudi Arabia

&nbsp;
<span style="font-style: normal; font-variant: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 7pt; line-height: normal;">&nbsp;·<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-variant-position: normal; font-stretch: normal; font-size: 7pt; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With investments exceeding SAR 450 million, EVA Pharma is moving steadfastly with the launch of a 50+ thousands sqm research &amp; manufacturing complex in the heart of Saudi Arabia.
·<span style="font-style: normal; font-variant: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 7pt; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The complex will serve a variety of therapeutic areas, with more than 150 pharmaceutical products covering the fields of oncology, immunosuppressants, vaccines, biologics and a wide range of treatments that require advanced technologies.
·<span style="font-style: normal; font-variant: normal; font-kerning: auto; font-optical-sizing: auto; font-feature-settings: normal; font-variation-settings: normal; font-weight: normal; font-stretch: normal; font-size: 7pt; line-height: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The MoU with the Ministry of Investment emphasizes a crucial collaboration between the private sector and the government to build Saudi Arabia’s bio-manufacturing market capabilities.
Riyadh, Saudi Arabia — December 13, 2023, EVA Pharma, one of the fastest-growing pharmaceutical companies in the Middle East and Africa (MEA), solidifies its unwavering dedication to the Saudi market with a series of monumental achievements. This includes the groundbreaking ceremony for the state-of-the-art pharmaceutical research and manufacturing complex in Sudair and the inauguration of its Riyadh office. Additionally, EVA Pharma proudly affirms its strategic partnership with the Ministry of Investment through the signing of a MoU as part of the ceremony.
The industrial complex aims to become a center of gravity for pharmaceutical manufacturing in the region with sustainable accessibility for innovative healthcare solutions. It will comprise an R&amp;D center and five pharmaceutical factories, including one for immunosuppressants and oncology products, another facility for biologics, a vaccines production unit, in addition to a facility for oral dosage forms like DPIs, Bi-layer tablets, and ODT. The complex will produce over 150 pharmaceutical products, spanning various therapeutic areas and addressing the most demanding health challenges in the Kingdom.
"On the personal level &amp; as a representative of the 5000 people in EVA Pharma we feel very blessed to be here &amp; we feel very excited about what we can bring to Saudi patients &amp; to Arab patients in the next months &amp; years. This assembly of manufacturing facilities will bring cutting-edge technologies to Saudi, so that Saudi can reach the healthcare independence that it aspires to have”; said Riad Armanious, CEO of EVA Pharma.
“This is a project that has had a tremendous support in every milestone and as we break-ground today for this first-of-its-kind cluster in the Kingdom, we will maintain our momentum &amp; we will have production in the very near future. We feel that we are doing the right thing, in the right time and in the right place. 
We are grateful for the Saudi support, thank you for all those who have helped us, inspired us, &amp; we promise, we’re here to collaborate &amp; we’re here to bring cutting edge technologies to meet unmet patients’ needs.”
EVA Pharma's strategic move into Saudi Arabia underscores its dedication to meeting unmet patient needs and marks its initial steps in the Saudi market through substantial local investments. By establishing a pharmaceutical research and manufacturing complex in Sudair, EVA Pharma aims to contribute to the Kingdom's Vision 2030 healthcare goals of increasing the production of local pharmaceutical products. The health sector transformation program aims to raise the private sector's contribution to 50%, a substantial increase from the current 11%.
The Sudair complex is designed by German consultancy IO, the complex embodies a green circular economy approach. The design of the complex not only pays homage to cultural roots but also strategically minimizes heat gain, thereby significantly reducing its carbon footprint. Contributing to the overall reduction of environmental impact, the complex will incorporate solar panels, on-site water recycling and waste treatment systems. Showcasing EVA Pharma’s environmentally conscious approach that aligns seamlessly with Saudi Arabia's vision for a greener and more sustainable future.
&nbsp;
About EVA Pharma for Industry
EVA Pharma for Industry is a subsidiary of EVA Pharma Holdings, one of the fastest-growing healthcare companies in the Middle East and Africa. EVA Pharma for Industry is registered in the Kingdom of Saudi Arabia as a local pharmaceutical manufacturer with a focus on sustainability and local investment in the Kingdom.
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals in 40+ countries, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
&nbsp;

thumbnail_MoU-MISA-EVA-Pharma-test.png

MoU-MISA-EVA-Pharma-test.png

EVA Pharma Announces Groundbreaking of its Research & Manufacturing Complex in Sudair and Unveils Revolutionary Partnership with the Ministry of Investment

·Riyadh, Saudi Arabia — October 23, 2024,&nbsp;EVA Pharma&nbsp;one of the fastest-growing pharmaceutical companies in the Middle East and Africa, has signed an agreement with Al-Dawaa Medical Services Company to strengthen their collaboration and provide high quality pharmaceuticals in the Saudi market. This partnership aims to ensure sustainable access to essential medicines and meet the healthcare needs of citizens.
The&nbsp;agreement was signed today on the sidelines of the Global Health Exhibition in Riyadh. Within the collaboration, both parties will work to improve the availability of high-quality medicines by developing logistics services and optimizing reliance on digital transformation to ensure that production and distribution adhere to the highest quality standards. Additionally, EVA Pharma and AlDawaa will provide accurate information about the medications to educate people about diseases and available treatments, maximizing the impact on the quality of life.
The partnership will also include developing proactive strategies aimed at addressing any challenges that could hinder the manufacturing or supply of medicines, while ensuring affordable prices for the local market, maintaining a steady supply, and ensuring the stability of the Saudi market.
Dr. Amgad Talaat, Regional Director of EVA Pharma Saudi Arabia and Director of Strategic Alliances, said that&nbsp;the collaboration between the two companies is part of EVA Pharma's commitment to expanding the localization of pharmaceutical and medicine manufacturing in Saudi Arabia.&nbsp;"This effort includes a series of major achievements, such as the establishment of our advanced industrial complex&nbsp;for research and manufacturing in Sudair Industrial City and the opening of EVA Pharma’s scientific office in Riyadh, in addition to collaborating with various entities to facilitate the availability of high-quality advanced medicines at affordable prices for Saudi patients."
&nbsp;
Mr.&nbsp;Fahd Al-Faraj, Executive Vice President of Al-Dawaa Medical Services Company,&nbsp;emphasized Al-Dawaa’s commitment to leveraging its capabilities and its dedication to forming fruitful partnerships to serve a large number of patients by making the medications manufactured by EVA Pharma available in the Kingdom. He also stressed the importance of supporting all efforts to localize advanced industries in Saudi Arabia in line with Vision 2030's goals for developing the healthcare sector.
This cooperation comes as part of efforts to support the healthcare sector in the Kingdom, in line with Saudi Vision 2030, which aims to enhance healthcare development and achieve self-sufficiency in the pharmaceutical sector.
--End of Press Release--
&nbsp;About EVA Pharma for Industry
EVA Pharma for Industry is a subsidiary of EVA Pharma Holdings, one of the fastest-growing healthcare companies in the Middle East and Africa while operating in more than 70 countries worldwide. EVA Pharma for Industry is registered in the Kingdom of Saudi Arabia as a local pharmaceutical manufacturer with a focus on sustainability and local investment in the Kingdom.
EVA Pharma is dedicated to improving access to affordable, high-quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology at two research centers bringing first-of-its-kind capabilities to the Middle East and Africa including mRNA research and development from AI prediction to biological products.
With a 5,000-strong team of professionals, EVA Pharma produces more than one million healthcare products a day at four state-of-the-art manufacturing facilities, which are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
Guided by a relentless drive to ensure sustainable access to pressing yet unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: Anti-infectives, metabolic health, bone, neuroscience, oncology, respiratory, gynecology, urology and andrology, pediatrics, ophthalmology, gastrointestinal tract, family medicine to meet both local and international demand.
For more information, please visit: <a href="https://www.evapharma.com/en-SA">https://www.evapharma.com/en-SA</a> or follow us on <a href="https://twitter.com/EVAPharma_MEA">X</a>, <a href="https://www.linkedin.com/company/eva-pharma/" target="_blank" rel="noopener">LinkedIn</a> &amp; <a href="https://www.instagram.com/evapharma_middle_east/" target="_blank" rel="noopener">Instagram</a> &nbsp;
&nbsp;
<div style="mso-element: endnote-list;">
<div id="edn1" style="mso-element: endnote;"></div>
</div>

thumbnail_EVAxKSA-al-dawaa-part-web2.png

EVAxKSA-al-dawaa-part-web2.png

EVA Pharma Collaborates with Al-Dawaa to Provide Sustainable Access to High-Quality Medicines in the Saudi Market

Highlights

CDMO

Licensing from EVA Pharma

Licensing to EVA Pharma

thumbnail_Group 36312@2x.png

Group 36312@2x.png

CPHI Worldwide

Fill up the form and our team will get back to you shortly

Thanks for your interest in EVA Pharma

&nbsp;&nbsp;

thumbnail_partnership_hero.webp

partnership_hero.webp

We believe in the catalytic power of collaboration to create&nbsp;sustainable ventures.

gilead.svg

beonelogox8 1.svg

kent.svg

Artboard 1.svg

thumbnail_Lilly-AMC-Lockup-V-Red-RGB (1).jpg

Lilly-AMC-Lockup-V-Red-RGB (1).jpg

Our Current Collaborations in Action

We are glad to expand our B2B business through Licensing, CDMO, and CMO business to include more than 35 countries around the world.

B2B Partnership Map

We focus on highly differentiated and innovative products to complement our portfolio, we are open to different business models including licensing of FDF and/or Bulk with supply, in addition to Tech transfer&nbsp;
&nbsp;
Our areas of focus are :&nbsp;
.Biosimilars&nbsp;
.mRNA technology
.Small molecules with focus on oncology products and hormones&nbsp;
.Vaccines with focus on epidemic diseases, Flu and Covid&nbsp;

In-Licensing (1).svg

In-Licensing

We offer a product list of more than 35 products in EU CTD format including differentiated dosage forms like DPIs, Transdermal Patches, in addition to solid dosage forms, injectables, and eye drops.
&nbsp;
Through the past few years, we developed B2B partnerships with more than 20 well-recognized partners in Europe, who granted MAs and launched the products in more than 15 EU countries.
&nbsp;
Our products lies in different therapeutic areas including Antiemetics, Anti-infectives, Cardiovascular, Diabetes, Neurology, Ophthalmology, Pain, Respiratory, Rheumatology, Urology, and Andrology.

Out-Licensing (1).svg

Out-Licensing

Since EVA Pharma has 21 years experience in different dosage forms including tablets, hard and soft gelatin capsules, sachets, DPI, ampoules, vials, ophthalmic and sterile cephalosporins, we offer CDMO services with very competitive prices using our dedicated pilot area.
&nbsp;
Our experience has led us to have :
.More than 300 products in market&nbsp;
.More than 500 products in pipeline
.More than 100 scientists specialized in different dosage forms&nbsp;

contract manufacturing outline (1).svg

EVA Pharma is recognized as reliable, flexible,high quality with cost effective manufacturing organization, that led to establishing a good relationship with different customer in different territories.
We are currently supplying more than 30 products to Europe, United kingdom, and Canada&nbsp;
In 2023, a new technical transfer project will start to supply more thaan 20 products to USA, UK, Australia, South America and Europe.

© 2026 Eva Pharma All Rights Reserved